# EDGAR Filing Document

**Accession Number:** 0001434265
**File Stem:** 0001434265-26-000002
**Filing Date:** 2026-1
**Character Count:** 25296
**Document Hash:** 10e701168a0f1c9eb08fab98739b4735
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001434265-26-000002.hdr.sgml**: 20260116

**ACCESSION NUMBER**: 0001434265-26-000002

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260116

**FILED AS OF DATE**: 20260116

**DATE AS OF CHANGE**: 20260116

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENMAB A/S
- **CENTRAL INDEX KEY:** 0001434265
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38976
- **FILM NUMBER:** 26538690

**BUSINESS ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

**MAIL ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**<br>FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF JANUARY 2026**

**COMMISSION FILE NUMBER 001-38976** 

**Genmab A/S**<br> (Exact name of Registrant as specified in its charter)

**Carl Jacobsens Vej 30**

**2500 Valby**

**Denmark**

**+45 70 20 27 28**<br> (Address of principal executive offices)<br>

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description of Exhibit</u> |
| 99.1 | <u>[Company Announcement Dated January 16, 2026](gmab_20260116xex99d1.htm)</u> |

---

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| GENMAB A/S | GENMAB A/S |
| BY: | /s/ Anthony Pagano |
| | Name: Anthony Pagano |
| | Title: Executive Vice President & Chief Financial Officer |

---

**DATE: January 16, 2026**

## Exhibit 99.1

**Exhibit 99.1**

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

**Company Announcement** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Based on the topline results from the EPCORE**<sup>®</sup> **DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps**

**COPENHAGEN, Denmark; January 16, 2026 – <u>Genmab A/S</u> (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab,** a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])<sup>1</sup> in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an improvement in PFS in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The study demonstrated an overall survival (OS) of HR: 0.96 [95% CI 0.77 to 1.20], which did not reach statistical significance.

The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy (73% had received two or more prior lines) who were ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). The study evaluated the safety and efficacy of epcoritamab monotherapy compared to investigator's choice of either rituximab plus gemcitabine and oxaliplatin (R-GemOx), or bendamustine plus rituximab (BR).

The adverse events observed in this study appear consistent with the known safety profile of epcoritamab. Further analysis of the results is ongoing, including the potential impact of various factors, such as the COVID-19 pandemic and increasing availability of novel anti-lymphoma therapies. The full trial results will be submitted for presentation at a future medical meeting. Genmab and AbbVie will engage with global regulatory authorities to discuss next steps.

Data is anticipated in 2026 from two Phase 3 trials evaluating fixed duration epcoritamab in patients with DLBCL, including EPCORE DLBCL-2, a front-line study evaluating epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), and EPCORE DLBCL-4, evaluating epcoritamab in combination with lenalidomide versus chemo-immunotherapy in patients with relapsed or refractory DLBCL.

"The EPCORE DLBCL-1 trial is the first Phase 3 study evaluating a bispecific antibody monotherapy to demonstrate improvements in progression-free survival in patients with relapsed or refractory DLBCL," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "The results from this global trial contribute to the growing body of evidence supporting epcoritamab and build upon the robust foundation established by epcoritamab, which has been used to treat thousands of patients in need of additional therapeutic options. Together with our partner, AbbVie, we remain deeply committed to advancing the development of epcoritamab as a potential core therapy across a broad range of B-cell malignancies."

Epcoritamab (approved under the brand name EPKINLY<sup>®</sup> in countries including the U.S. and Japan, and as TEPKINLY<sup>®</sup> in the European Union) has received regulatory approval in certain lymphoma indications in more than 65 countries. Genmab and AbbVie remain committed to advancing the potential of epcoritamab,

<sup>\*</sup>Based on intent-to-treat principle.

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 1/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

with ongoing clinical programs evaluating the therapy as a monotherapy and in combination regimens across treatment lines and a broad range of hematologic malignancies.

**About Diffuse Large B-Cell Lymphoma**

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.<sup>i,ii</sup> In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.<sup>iii</sup> DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.<sup>iv,v</sup> DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.<sup>iv,vi</sup>

**About the EPCORE DLBCL-1 Trial** 

EPCORE DLBCL-1 (<u>NCT04628494</u>) is a global Phase 3 open label, multi-center, randomized trial to evaluate the efficacy of epcoritamab (GEN3013, DuoBody<sup>®</sup>-CD3xCD20) compared to investigator's choice of chemotherapy, either rituximab plus gemcitabine plus and oxaliplatin (R-GemOx), or bendamustine plus rituximab (BR), in patients with relapsed or refractory DLBCL who are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). The trial started on January 13, 2021, and is ongoing.

More information on this trial can be found at <u>https://www.clinicaltrials.gov/</u>.

**About Epcoritamab** 

Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.<sup>vii</sup> 

Epcoritamab (approved under the brand name EPKINLY<sup>®</sup> in the U.S. and Japan, and TEPKINLY<sup>®</sup> in the EU) has received regulatory approval in certain lymphoma indications in several territories. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes three ongoing Phase 3, open-label, randomized trials, among them a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (<u>NCT05578976</u>), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (<u>NCT06508658</u>), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R<sup>2</sup>) compared to chemoimmunotherapy in patients with previously untreated FL (<u>NCT06191744</u>). The safety

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 2/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

and efficacy of epcoritamab has not been established for these investigational uses. Please visit <u>www.clinicaltrials.gov</u> for more information.

**EPKINLY**<sup>®</sup> **(epcoritamab-bysp) U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION**

**What is EPKINLY?**<br>EPKINLY is a prescription medicine used to treat adults with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.

oEPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• follicular lymphoma (FL) that has come back or that did not respond after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

**Important Warnings—EPKINLY can cause serious side effects, including:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Neurologic problems** that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

**People with DLBCL or high-grade B-cell lymphoma** should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

**People with follicular lymphoma (FL)** may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.

**Tell your healthcare provider or get medical help right away** if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

**EPKINLY can cause other serious side effects, including:**

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 3/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Low blood cell counts,** which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

**Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you** have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

**The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include** CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results with EPKINLY when used alone** include decreased white blood cells, decreased red blood cells, and decreased platelets.

**The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include** rash**,** upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. **The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab** include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

**Please see <u>Full Prescribing Information</u> and <u>Medication Guide</u>, including Important Warnings.**

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 4/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

**<u>Globally, prescribing information varies; refer to the individual product label for complete information.</u>**

**About Genmab** <br>Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit <u>Genmab.com</u> and follow us on <u>LinkedIn</u> and <u>X</u>.<br>

**Contact:**&nbsp;&nbsp;&nbsp;&nbsp;<br>Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: <u>mmp@genmab.com</u>

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: <u>acn@genmab.com</u> 

<br>*This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on <u>www.genmab.com</u> and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at <u>www.sec.gov</u>. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.*

*Genmab A/S and/or its subsidiaries own the following trademarks: Genmab*<sup>®</sup>*; the Y-shaped Genmab logo*<sup>®</sup>*; Genmab in combination with the Y-shaped Genmab logo*<sup>®</sup>*; HuMax*<sup>®</sup>*; DuoBody*<sup>®</sup>*; HexaBody*<sup>®</sup>*; DuoHexaBody*<sup>®</sup>*, HexElect*<sup>®</sup> *and KYSO™. EPCORE*<sup>®</sup>*, EPKINLY*<sup>®</sup>*, TEPKINLY*<sup>®</sup> *and their designs are trademarks of AbbVie Biotechnology Ltd.*

<sup>i</sup> Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed December 2025. HYPERLINK "https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/" https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl

<sup>ii</sup> Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 5/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Genmab Announces Topline Results for Epcoritamab (DuoBody**<sup>®</sup> **CD3xCD20) from Phase 3 EPCORE**<sup>®</sup> **DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)**

<sup>iii</sup> Leukemia and Lymphoma Society. Diffuse Large B-Cell Lymphoma (DLBCL). Accessed November 2024. HYPERLINK "https://c212.net/c/link/?t=0&l=en&o=4500289-1&h=2764746432&u=https%3A%2F%2Fwww.lls.org%2Fresearch%2Fdiffuse-large-b-cell-lymphoma-dlbcl&a=https%3A%2F%2Fwww.lls.org%2Fresearch%2Fdiffuse-large-b-cell-lymphoma-dlbcl" \t "_blank" https://www.lls.org/research/diffuse-large-b-cell-lymphoma-dlbcl

<sup>iv</sup> Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612

<sup>v</sup> Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188

<sup>vi</sup> Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620

<sup>vii</sup> Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625

Genmab A/S&nbsp;&nbsp;&nbsp;&nbsp;Tel: +45 7020 2728&nbsp;&nbsp;&nbsp;&nbsp;Company Announcement no. 01

Carl Jacobsens Vej 30&nbsp;&nbsp;&nbsp;&nbsp;www.genmab.com&nbsp;&nbsp;&nbsp;&nbsp;Page 6/6

2500 Valby, Denmark&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR no. 2102 3884

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEI Code 529900MTJPDPE4MHJ122